The U.S. Food and Drug Administration (FDA) has approved Veppanu (vepdegestrant), marking a significant milestone in the ...
New breast cancer pill eliminates tumor proteins and improves treatment response in patients by making the estrogen receptor ...
US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Stage II and III ...
Approval received in advance of FDA-assigned PDUFA date of June 5, 2026; Arvinas and Pfizer remain on track to announce selection of a third party – – VEPPANU offers a new therapeutic option in ...
Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually ...
Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the ...
In this segment, Dr. Gregory Vidal discusses the role of estrogen receptor antagonists in the treatment of ER-positive, HER2-negative metastatic breast cancer following progression on prior endocrine ...
LA JOLLA (May 12, 2025)—A new Salk Institute study suggests estrogen-related receptors could be a key to repairing energy metabolism and muscle fatigue. Across the body, tiny bean-shaped structures ...
A new Salk Institute study suggests estrogen-related receptors could be a key to repairing energy metabolism and muscle fatigue. Across the body, tiny bean-shaped structures called mitochondria turn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results